Company
CytoAgents
Innovative Treatment for a Pipeline of Inflammatory Indications
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2018
Claim, correct or request removal
Record updated 28 September 2026
About
CytoAgents is advancing CTO1681 for multiple indications where dysregulated cytokine signaling plays a central role in disease pathogenesis. Therapeutic indications include pulmonary arterial hypertension (PAH), asthma, atopic dermatitis (AD), and inflammation within the tumor microenvironment.
Funding snapshot
- Total raised
- $13.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $7M2023-05-03
Funding rounds
- Round, 2023
- $7M2023-05-03, SEC form D sold, 23 investors
- Round, 2021
- $6.1M2021-07-30, SEC form D sold, 23 investors
Products
- Other
- CTO1681
Loading relationship preview